New life sciences research: Speed to market, medication adherence hinges on rethinking engagement solutions

Life sciences organizations face growing pressure to engage patients more effectively across the entire lifecycle—from trial recruitment and retention to post-launch adherence and long-term outcomes. While leaders recognize the importance of patient-centered engagement, new research shows that most organizations still rely on fragmented, non-scalable approaches that struggle to meet rising expectations for personalization, speed, and consistency.

Based on a Q4 2025 survey of 75 U.S. life sciences leaders, Lirio’s latest market report uncovers how engagement gaps are impacting trial performance, commercialization success, and emerging direct-to-patient strategies.

In Lirio’s life sciences market report, you’ll learn:

• Why patient engagement challenges are the top barrier to both trial success and post-launch adherence
• How reliance on site-level and homegrown tools limits scalability and personalization
• Where engagement gaps slow speed-to-market and create downstream operational risk
• What life sciences leaders prioritize as they shift from HCP to more direct, patient-centered engagement models